Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines

Jones, Christopher M.; McAninch, Jana K.

doi:10.1016/j.amepre.2015.03.040

Cited by 320 publications

(252 citation statements)

References 18 publications

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…Three studies of fatal overdose deaths found evidence of concurrent benzodiazepine use in 31%-61% of decedents (67,128,129). In one of these studies (67), among decedents who received an opioid prescription, those whose deaths were related to opioids were more likely to have obtained opioids from multiple physicians and pharmacies than decedents whose deaths were not related to opioids.…”

Section: Benefits and Harms Of Opioid Therapymentioning

confidence: 99%

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Haegerich²,

2016

View full text Add to dashboard Cite

Section: Benefits and Harms Of Opioid Therapymentioning

confidence: 99%

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Haegerich²,

2016

View full text Add to dashboard Cite

“…Moreover, it adds to the possible dangers arising from polydrug use [25,26]. One corollary to the dangers perhaps also includes harmful drug interactions [27]. Other observers, however, emphasize the possibility of substitution of NPS existing for more dangerous drugs [28,29].…”

Section: Defining the Problemmentioning

confidence: 97%

Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill

2016

View full text Add to dashboard Cite

The regulation of new psychoactive substances (NPS) has confounded governments throughout the western world. In 2014 the UK government convened an NPS Review Expert Panel to consider a range of approaches. Ultimately the Panel recommended that the government ban all new psychoactive drugs and allow only psychoactive substances specifically exempted, such as alcohol, tobacco and those allowed as medicines. The government introduced the Psychoactive Substances Bill (PSB) in response to that recommendation. Passed in 2016, the Bill has attracted a torrent of criticism from scientists and experts. The Bill could be improved with revision, but the problems of the total ban, as envisioned by the PSB, with respect to the NPS, may be inherent: (1) defining psychoactivity is conceptually fraught, with great consequence for the scope of the prohibition; (2) operationalizing psychoactivity as a usable concept for legal control purposes is extremely difficult, perhaps impossible; and (3) the detachment of penalties for violating a total ban from establishing the harmfulness of a substance is normatively troubling. Given the uncertainties about the effects of a total ban, it is appropriate at this time for other governments to assess more fully the nature of the NPS problem, and the potential control approaches.

show abstract

“…La peligrosa combinación de estos medicamentos está conduciendo a un aumento de las sobredosis y muertes en Estados Unidos. Una revisión reciente de la FDA (Food and Drug Administration) encontró que el creciente uso combinado de medicamentos opioides con benzodiacepinas u otros fármacos que deprimen el sistema nervioso central (SNC) produjo efectos secundarios graves, a veces fatales, incluyendo dificultad respiratoria y muerte (1,2). La FDA llegó a de tener una sobredosis fatal.…”

Section: ¿Necesitan Nuestros Pacientes Opioides Y Benzodiacepinas Deunclassified

¿Necesitan nuestros pacientes opioides y benzodiacepinas de forma concomitante?

Alcántara-Montero¹,

González-Curado²

2017

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines

Cited by 320 publications

References 18 publications

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill

¿Necesitan nuestros pacientes opioides y benzodiacepinas de forma concomitante?

Contact Info

Product

Resources

About